|
EQS-News: Medios AG
/ Key word(s): Investment
Press Release Medios AG: Successful sale of shares from Company founder Manfred Schneider to Luxempart S.A. Berlin, June 20, 2024 – Medios, a leading provider of Specialty Pharma in Europe, was today informed that Manfred Schneider has reallocated all of his shares in Medios AG. Schneider’s shares, which corresponds to a total of 14.9% of Medios’ share capital, were sold to the investment company Luxempart S.A. as part of a private placement. Schneider had held some of the shares sold via his companies Tangaroa Management GmbH and Tangaroa GmbH & Co. KG. Matthias Gaertner, Chairman of the Executive Board of Medios: “On behalf of the Executive Board, I would like to thank Manfred Schneider for his many years of commitment to Medios. As founder and former CEO, he has had a strong influence on our Company. With his clear vision and the right strategic decisions, he laid the foundation for the dynamic growth and ongoing success of the Medios Group. With the establishment of a European Specialty Pharma platform, we are currently at an exciting turning point. We are therefore very pleased to have Luxempart as a new strategic anchor shareholder and are convinced that Luxempart is exactly the right partner for the internationalization of our Company, which has just begun, and the associated next phase of growth. As a solid, internationally experienced strategic investor with a well-founded network and know-how, Luxempart can support us very well in this process.”
About Luxempart Luxempart is a Luxembourg-based listed investment company with a net worth of EUR 2.3bn backed by Luxembourgish entrepreneurial families. With permanent capital and a professional investment team, Luxempart provides flexible long-term financing solutions to entrepreneurs, families and management and actively supports its portfolio companies in their growth and international expansion. Luxempart’s Direct Investment strategy consists in investing equity tickets ranging from €25m up to €100m in the DACH region, France, Benelux countries and Northern Italy.
About Medios AG Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company and is listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Medios AG Heidestraße 9 | 10557 Berlin T +49 30 232 566 800
Disclaimer This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.
20.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 - 800 |
| Fax: | +49 30 232 566 - 801 |
| E-mail: | ir@medios.ag |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1929793 |
| End of News | EQS News Service |
|
|
1929793 20.06.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
